查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1671994

全球尿路上皮癌诊断市场：产业分析、规模、份额、成长、趋势和预测（2025-2032 年）

Urothelial Carcinoma Diagnostics Market: Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2025 - 2032
出版日期: | 出版商: Persistence Market Research | 英文 191 Pages | 商品交期: 2-5个工作天内

价格
简介目录

预计 2025 年全球尿路上皮癌诊断市场规模将达到 18.448 亿美元，到 2032 年将达到 38.313 亿美元，预测期内（2025-2032 年）的复合年增长率为 10.9%。

尿路上皮癌，通常称为膀胱癌，是一种恶性肿瘤，需要早期准确诊断才能有效治疗并改善患者预后。尿路上皮癌诊断市场包括各种诊断方式，例如尿液细胞学、生物标记测试、萤光杂合反应(FISH)、膀胱镜检查和影像技术。这些诊断方法在疾病检测、分期和復发监测中发挥重要作用。市场成长的动力包括诊断技术的进步、膀胱癌发病率的增加、非侵入性诊断方法的日益普及、患者的便利性和早期发现率的提高。

全球尿路上皮癌诊断市场受到几个关键因素的推动，包括膀胱癌盛行率的上升，尤其是在老化人口和吸烟、接触工业化学物质等高风险因素的人群中。此外，人们对尿液生物标记检测等非侵入性、微创诊断方法的日益偏好也促进了市场的扩张。此外，分子诊断和人工智慧成像解决方案的技术进步正在提高诊断的准确性和效率。液态切片和次世代定序(NGS) 的日益融合也透过为尿路上皮癌患者提供准确和个性化的诊断见解进一步推动了市场成长。

由于人工智慧和机器学习在诊断影像中的应用越来越多、精准医疗方法的不断扩大以及对早期癌症检测计划的日益关注，尿路上皮癌诊断市场提供了巨大的成长机会。数位病理学和人工智慧辅助诊断平台的进步将提高诊断效率，减少假阳性或假阴性的机会，并改善患者的治疗效果。此外，开发具有成本效益、快速的照护现场上皮癌即时诊断解决方案可能会促进服务不足地区的市场发展。诊断公司和研究机构之间为推进生物标誌物的发现和检验建立的合作伙伴关係也为这个发展中市场提供了丰厚的成长前景。

本报告研究了全球尿路上皮癌诊断市场，提供了对产品、测试、最终用户和地区的趋势以及参与市场的公司概况的见解。

目录

第一章执行摘要

第二章 市场概况

  • 市场范围和定义
  • 市场动态
  • 宏观经济因素
  • COVID-19影响分析
  • 预测因子－相关性和影响力

第 3 章 增值洞察

第四章全球尿路上皮癌诊断市场展望

  • 主要亮点
  • 市场规模分析及预测
  • 全球尿路上皮癌诊断市场（按产品）展望
  • 全球尿路上皮癌诊断市场前景（按测试）
  • 全球尿路上皮癌诊断市场前景（按最终用户）

5. 全球尿路上皮癌诊断市场按地区展望

  • 主要亮点
  • 2019 年至 2024 年按地区分類的历史市场规模分析
  • 2025 年至 2032 年各地区当前市场规模分析及预测
  • 按地区分析市场吸引力

6. 北美尿路上皮癌诊断市场展望

7. 欧洲尿路上皮癌诊断市场展望

第 8 章东亚尿路上皮癌诊断市场展望

9. 南亚和大洋洲尿路上皮癌诊断市场展望

10. 拉丁美洲尿路上皮癌诊断市场展望

第 11 章中东和非洲尿路上皮癌诊断市场展望

第十二章 竞争格局

  • 2025 年市场占有率分析
  • 市场结构
  • 公司简介（详情－概述、财务状况、策略、最新发展）
    • Roche Holding
    • Illumina
    • IDL Biotech
    • Agilent Technologies
    • Olympus Corporation
    • Philips Healthcare
    • Abbott Molecular
    • Bio-Rad Laboratories, Inc.
    • Thermo Fisher Scientific, Inc.（Qiagen NV）
    • Danaher Corporation（Cepheid）
    • GE Healthcare
    • Pacific Edge
    • Nonacus Limited
    • KDx Diagnostics Inc.
    • Sysmex Europe SE

第十三章 附录

简介目录
Product Code: PMRREP14128

Persistence Market Research has recently released a comprehensive report on the worldwide market for urothelial carcinoma diagnostics. The report offers a thorough assessment of crucial market dynamics, including drivers, trends, opportunities, and challenges, providing detailed insights into the market structure. This research publication presents exclusive data and statistics outlining the anticipated growth trajectory of the global urothelial carcinoma diagnostics market from 2025 to 2032.

Key Insights:

  • Urothelial Carcinoma Diagnostics Market Size (2025E): US$ 1,844.8 Mn
  • Projected Market Value (2032F): US$ 3,831.3 Mn
  • Global Market Growth Rate (CAGR 2025 to 2032): 10.9%

Urothelial Carcinoma Diagnostics Market - Report Scope:

Urothelial carcinoma, commonly referred to as bladder cancer, is a prevalent malignancy requiring early and accurate diagnostics for effective treatment and patient outcomes. The market for urothelial carcinoma diagnostics includes a range of diagnostic modalities such as urine cytology, biomarker testing, fluorescence in situ hybridization (FISH), cystoscopy, and imaging techniques. These diagnostics play a crucial role in disease detection, staging, and monitoring recurrence. Market growth is driven by advancements in diagnostic technologies, increasing bladder cancer incidence, and the growing adoption of non-invasive diagnostic approaches, improving patient convenience and early detection rates.

Market Growth Drivers:

The global urothelial carcinoma diagnostics market is propelled by several key factors, including the rising prevalence of bladder cancer, particularly among aging populations and individuals with high-risk factors such as smoking and exposure to industrial chemicals. The growing preference for non-invasive and minimally invasive diagnostic methods, such as urine-based biomarker tests, is also contributing to market expansion. Additionally, technological advancements in molecular diagnostics and artificial intelligence-driven imaging solutions are enhancing diagnostic accuracy and efficiency. The increasing integration of liquid biopsy and next-generation sequencing (NGS) further supports market growth by offering precise, personalized diagnostic insights for urothelial carcinoma patients.

Market Restraints:

Despite promising growth prospects, the urothelial carcinoma diagnostics market faces challenges related to high diagnostic costs, limited accessibility in low-income regions, and reimbursement constraints. Many advanced diagnostic tests, including biomarker-based assays and genetic testing, remain expensive, limiting their widespread adoption in cost-sensitive markets. Furthermore, the complexity of regulatory approvals for novel diagnostic techniques poses barriers to market entry and innovation. Addressing these challenges requires collaboration among diagnostic manufacturers, healthcare providers, and policymakers to enhance affordability, accessibility, and regulatory harmonization.

Market Opportunities:

The urothelial carcinoma diagnostics market presents significant growth opportunities driven by the increasing adoption of artificial intelligence and machine learning in diagnostic imaging, the expansion of precision medicine approaches, and the rising focus on early cancer detection programs. Advancements in digital pathology and AI-assisted diagnostic platforms enhance diagnostic efficiency and reduce the likelihood of false positives or negatives, improving patient outcomes. Additionally, the development of cost-effective, rapid point-of-care diagnostic solutions for urothelial carcinoma could drive market penetration in underserved regions. Partnerships between diagnostic companies and research institutions to advance biomarker discovery and validation also offer lucrative growth prospects in this evolving market.

Key Questions Answered in the Report:

  • What are the primary factors driving the growth of the urothelial carcinoma diagnostics market globally?
  • Which diagnostic modalities are witnessing the highest adoption in urothelial carcinoma detection and management?
  • How are technological advancements influencing the competitive landscape of the urothelial carcinoma diagnostics market?
  • Who are the key players contributing to the urothelial carcinoma diagnostics market, and what strategies are they employing to maintain market relevance?
  • What are the emerging trends and future prospects in the global urothelial carcinoma diagnostics market?

Competitive Intelligence and Business Strategy:

Leading players in the global urothelial carcinoma diagnostics market, including Roche Diagnostics, Abbott Laboratories, Thermo Fisher Scientific, and Bio-Rad Laboratories, focus on technological innovation, strategic collaborations, and product development to gain a competitive edge. These companies invest heavily in R&D to develop novel biomarker assays, liquid biopsy solutions, and AI-driven imaging tools for early and accurate detection of urothelial carcinoma. Partnerships with academic institutions and clinical research organizations facilitate the advancement of precision oncology diagnostics. Additionally, efforts to improve accessibility and affordability through pricing strategies, reimbursement advocacy, and expansion into emerging markets further support market growth.

Key Companies Profiled:

  • Roche Diagnostics
  • Abbott Laboratories
  • Thermo Fisher Scientific
  • Bio-Rad Laboratories
  • Qiagen N.V.
  • Agilent Technologies
  • Illumina, Inc.
  • Siemens Healthineers
  • BD (Becton, Dickinson and Company)
  • Hologic, Inc.

Urothelial Carcinoma Diagnostics Market Segmentation

By Product

  • Reagent and Kits
  • Instruments

By Test

  • Urinalysis Test
  • Molecular Diagnostic Test
  • Biomarker Test

Cell-Based Test

  • Imaging Test
  • Cystoscopy
  • Ureteroscopy

By End User

  • Hospitals
  • Diagnostic Laboratories
  • Research and Academic Institutes
  • Clinical Research Organizations

By Region

  • North America
  • Europe
  • East Asia
  • South Asia and Oceania
  • Middle East and Africa
  • Latin America

Table of Contents

1. Executive Summary

  • 1.1. Global Urothelial Carcinoma Diagnostics Market Snapshot, 2025 and 2032
  • 1.2. Market Opportunity Assessment, 2025-2032, US$ Mn
  • 1.3. Key Market Trends
  • 1.4. Future Market Projections
  • 1.5. Premium Market Insights
  • 1.6. Industry Developments and Key Market Events
  • 1.7. PMR Analysis and Recommendations

2. Market Overview

  • 2.1. Market Scope and Definition
  • 2.2. Market Dynamics
    • 2.2.1. Drivers
    • 2.2.2. Restraints
    • 2.2.3. Opportunity
    • 2.2.4. Challenges
    • 2.2.5. Key Trends
  • 2.3. Macro-Economic Factors
    • 2.3.1. Global Sectorial Outlook
    • 2.3.2. Global GDP Growth Outlook
  • 2.4. COVID-19 Impact Analysis
  • 2.5. Forecast Factors - Relevance and Impact

3. Value Added Insights

  • 3.1. Regulatory Landscape
  • 3.2. Product Adoption Analysis
  • 3.3. Value Chain Analysis
  • 3.4. Key Deals and Mergers
  • 3.5. PESTLE Analysis
  • 3.6. Porter's Five Force Analysis

4. Global Urothelial Carcinoma Diagnostics Market Outlook:

  • 4.1. Key Highlights
    • 4.1.1. Market Size (US$ Mn) and Y-o-Y Growth
    • 4.1.2. Absolute $ Opportunity
  • 4.2. Market Size (US$ Mn) Analysis and Forecast
    • 4.2.1. Historical Market Size (US$ Mn) Analysis, 2019-2024
    • 4.2.2. Current Market Size (US$ Mn) Analysis and Forecast, 2025-2032
  • 4.3. Global Urothelial Carcinoma Diagnostics Market Outlook: Product
    • 4.3.1. Introduction / Key Findings
    • 4.3.2. Historical Market Size (US$ Mn) Analysis, By Product, 2019-2024
    • 4.3.3. Current Market Size (US$ Mn) Analysis and Forecast, By Product, 2025-2032
      • 4.3.3.1. Reagent and Kits
      • 4.3.3.2. Instruments
    • 4.3.4. Market Attractiveness Analysis: Product
  • 4.4. Global Urothelial Carcinoma Diagnostics Market Outlook: Test
    • 4.4.1. Introduction / Key Findings
    • 4.4.2. Historical Market Size (US$ Mn) Analysis, By Test, 2019-2024
    • 4.4.3. Current Market Size (US$ Mn) Analysis and Forecast, By Test, 2025-2032
      • 4.4.3.1. Urinalysis Test
      • 4.4.3.2. Molecular Diagnostic Test
      • 4.4.3.3. Biomarker Test
        • 4.4.3.3.1. Immuno-Histochemical Assay Test
        • 4.4.3.3.2. In Situ Hybridization Test
        • 4.4.3.3.3. Biopsy
        • 4.4.3.3.4. Cell-Based Test
      • 4.4.3.4. Imaging Test
      • 4.4.3.5. Cystoscopy
      • 4.4.3.6. Ureteroscopy
    • 4.4.4. Market Attractiveness Analysis: Test
  • 4.5. Global Urothelial Carcinoma Diagnostics Market Outlook: End User
    • 4.5.1. Introduction / Key Findings
    • 4.5.2. Historical Market Size (US$ Mn) Analysis, By End User, 2019-2024
    • 4.5.3. Current Market Size (US$ Mn) Analysis and Forecast, By End User, 2025-2032
      • 4.5.3.1. Hospitals
      • 4.5.3.2. Diagnostic Laboratories
      • 4.5.3.3. Research and Academic Institutes
      • 4.5.3.4. Clinical Research Organizations
    • 4.5.4. Market Attractiveness Analysis: End User

5. Global Urothelial Carcinoma Diagnostics Market Outlook: Region

  • 5.1. Key Highlights
  • 5.2. Historical Market Size (US$ Mn) Analysis, By Region, 2019-2024
  • 5.3. Current Market Size (US$ Mn) Analysis and Forecast, By Region, 2025-2032
    • 5.3.1. North America
    • 5.3.2. Europe
    • 5.3.3. East Asia
    • 5.3.4. South Asia and Oceania
    • 5.3.5. Latin America
    • 5.3.6. Middle East & Africa
  • 5.4. Market Attractiveness Analysis: Region

6. North America Urothelial Carcinoma Diagnostics Market Outlook:

  • 6.1. Key Highlights
  • 6.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2024
    • 6.2.1. By Country
    • 6.2.2. By Product
    • 6.2.3. By Test
    • 6.2.4. By End User
  • 6.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2025-2032
    • 6.3.1. U.S.
    • 6.3.2. Canada
  • 6.4. Current Market Size (US$ Mn) Analysis and Forecast, By Product, 2025-2032
    • 6.4.1. Reagent and Kits
    • 6.4.2. Instruments
  • 6.5. Current Market Size (US$ Mn) Analysis and Forecast, By Test, 2025-2032
    • 6.5.1. Urinalysis Test
    • 6.5.2. Molecular Diagnostic Test
    • 6.5.3. Biomarker Test
      • 6.5.3.1. Immuno-Histochemical Assay Test
      • 6.5.3.2. In Situ Hybridization Test
      • 6.5.3.3. Biopsy
      • 6.5.3.4. Cell-Based Test
    • 6.5.4. Imaging Test
    • 6.5.5. Cystoscopy
    • 6.5.6. Ureteroscopy
  • 6.6. Current Market Size (US$ Mn) Analysis and Forecast, By End User, 2025-2032
    • 6.6.1. Hospitals
    • 6.6.2. Diagnostic Laboratories
    • 6.6.3. Research and Academic Institutes
    • 6.6.4. Clinical Research Organizations
  • 6.7. Market Attractiveness Analysis

7. Europe Urothelial Carcinoma Diagnostics Market Outlook:

  • 7.1. Key Highlights
  • 7.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2024
    • 7.2.1. By Country
    • 7.2.2. By Product
    • 7.2.3. By Test
    • 7.2.4. By End User
  • 7.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2025-2032
    • 7.3.1. Germany
    • 7.3.2. France
    • 7.3.3. U.K.
    • 7.3.4. Italy
    • 7.3.5. Spain
    • 7.3.6. Russia
    • 7.3.7. Turkey
    • 7.3.8. Rest of Europe
  • 7.4. Current Market Size (US$ Mn) Analysis and Forecast, By Product, 2025-2032
    • 7.4.1. Reagent and Kits
    • 7.4.2. Instruments
  • 7.5. Current Market Size (US$ Mn) Analysis and Forecast, By Test, 2025-2032
    • 7.5.1. Urinalysis Test
    • 7.5.2. Molecular Diagnostic Test
    • 7.5.3. Biomarker Test
      • 7.5.3.1. Immuno-Histochemical Assay Test
      • 7.5.3.2. In Situ Hybridization Test
      • 7.5.3.3. Biopsy
      • 7.5.3.4. Cell-Based Test
    • 7.5.4. Imaging Test
    • 7.5.5. Cystoscopy
    • 7.5.6. Ureteroscopy
  • 7.6. Current Market Size (US$ Mn) Analysis and Forecast, By End User, 2025-2032
    • 7.6.1. Hospitals
    • 7.6.2. Diagnostic Laboratories
    • 7.6.3. Research and Academic Institutes
    • 7.6.4. Clinical Research Organizations
  • 7.7. Market Attractiveness Analysis

8. East Asia Urothelial Carcinoma Diagnostics Market Outlook:

  • 8.1. Key Highlights
  • 8.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2024
    • 8.2.1. By Country
    • 8.2.2. By Product
    • 8.2.3. By Test
    • 8.2.4. By End User
  • 8.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2025-2032
    • 8.3.1. China
    • 8.3.2. Japan
    • 8.3.3. South Korea
  • 8.4. Current Market Size (US$ Mn) Analysis and Forecast, By Product, 2025-2032
    • 8.4.1. Reagent and Kits
    • 8.4.2. Instruments
  • 8.5. Current Market Size (US$ Mn) Analysis and Forecast, By Test, 2025-2032
    • 8.5.1. Urinalysis Test
    • 8.5.2. Molecular Diagnostic Test
    • 8.5.3. Biomarker Test
      • 8.5.3.1. Immuno-Histochemical Assay Test
      • 8.5.3.2. In Situ Hybridization Test
      • 8.5.3.3. Biopsy
      • 8.5.3.4. Cell-Based Test
    • 8.5.4. Imaging Test
    • 8.5.5. Cystoscopy
    • 8.5.6. Ureteroscopy
  • 8.6. Current Market Size (US$ Mn) Analysis and Forecast, By End User, 2025-2032
    • 8.6.1. Hospitals
    • 8.6.2. Diagnostic Laboratories
    • 8.6.3. Research and Academic Institutes
    • 8.6.4. Clinical Research Organizations
  • 8.7. Market Attractiveness Analysis

9. South Asia & Oceania Urothelial Carcinoma Diagnostics Market Outlook:

  • 9.1. Key Highlights
  • 9.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2024
    • 9.2.1. By Country
    • 9.2.2. By Product
    • 9.2.3. By Test
    • 9.2.4. By End User
  • 9.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2025-2032
    • 9.3.1. India
    • 9.3.2. Southeast Asia
    • 9.3.3. ANZ
    • 9.3.4. Rest of South Asia & Oceania
  • 9.4. Current Market Size (US$ Mn) Analysis and Forecast, By Product, 2025-2032
    • 9.4.1. Reagent and Kits
    • 9.4.2. Instruments
  • 9.5. Current Market Size (US$ Mn) Analysis and Forecast, By Test, 2025-2032
    • 9.5.1. Urinalysis Test
    • 9.5.2. Molecular Diagnostic Test
    • 9.5.3. Biomarker Test
      • 9.5.3.1. Immuno-Histochemical Assay Test
      • 9.5.3.2. In Situ Hybridization Test
      • 9.5.3.3. Biopsy
      • 9.5.3.4. Cell-Based Test
    • 9.5.4. Imaging Test
    • 9.5.5. Cystoscopy
    • 9.5.6. Ureteroscopy
  • 9.6. Current Market Size (US$ Mn) Analysis and Forecast, By End User, 2025-2032
    • 9.6.1. Hospitals
    • 9.6.2. Diagnostic Laboratories
    • 9.6.3. Research and Academic Institutes
    • 9.6.4. Clinical Research Organizations
  • 9.7. Market Attractiveness Analysis

10. Latin America Urothelial Carcinoma Diagnostics Market Outlook:

  • 10.1. Key Highlights
  • 10.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2024
    • 10.2.1. By Country
    • 10.2.2. By Product
    • 10.2.3. By Test
    • 10.2.4. By End User
  • 10.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2025-2032
    • 10.3.1. Brazil
    • 10.3.2. Mexico
    • 10.3.3. Rest of Latin America
  • 10.4. Current Market Size (US$ Mn) Analysis and Forecast, By Product, 2025-2032
    • 10.4.1. Reagent and Kits
    • 10.4.2. Instruments
  • 10.5. Current Market Size (US$ Mn) Analysis and Forecast, By Test, 2025-2032
    • 10.5.1. Urinalysis Test
    • 10.5.2. Molecular Diagnostic Test
    • 10.5.3. Biomarker Test
      • 10.5.3.1. Immuno-Histochemical Assay Test
      • 10.5.3.2. In Situ Hybridization Test
      • 10.5.3.3. Biopsy
      • 10.5.3.4. Cell-Based Test
    • 10.5.4. Imaging Test
    • 10.5.5. Cystoscopy
    • 10.5.6. Ureteroscopy
  • 10.6. Current Market Size (US$ Mn) Analysis and Forecast, By End User, 2025-2032
    • 10.6.1. Hospitals
    • 10.6.2. Diagnostic Laboratories
    • 10.6.3. Research and Academic Institutes
    • 10.6.4. Clinical Research Organizations
  • 10.7. Market Attractiveness Analysis

11. Middle East & Africa Urothelial Carcinoma Diagnostics Market Outlook:

  • 11.1. Key Highlights
  • 11.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2024
    • 11.2.1. By Country
    • 11.2.2. By Product
    • 11.2.3. By Test
    • 11.2.4. By End User
  • 11.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2025-2032
    • 11.3.1. GCC Countries
    • 11.3.2. Egypt
    • 11.3.3. South Africa
    • 11.3.4. Northern Africa
    • 11.3.5. Rest of Middle East & Africa
  • 11.4. Current Market Size (US$ Mn) Analysis and Forecast, By Product, 2025-2032
    • 11.4.1. Reagent and Kits
    • 11.4.2. Instruments
  • 11.5. Current Market Size (US$ Mn) Analysis and Forecast, By Test, 2025-2032
    • 11.5.1. Urinalysis Test
    • 11.5.2. Molecular Diagnostic Test
    • 11.5.3. Biomarker Test
      • 11.5.3.1. Immuno-Histochemical Assay Test
      • 11.5.3.2. In Situ Hybridization Test
      • 11.5.3.3. Biopsy
      • 11.5.3.4. Cell-Based Test
    • 11.5.4. Imaging Test
    • 11.5.5. Cystoscopy
    • 11.5.6. Ureteroscopy
  • 11.6. Current Market Size (US$ Mn) Analysis and Forecast, By End User, 2025-2032
    • 11.6.1. Hospitals
    • 11.6.2. Diagnostic Laboratories
    • 11.6.3. Research and Academic Institutes
    • 11.6.4. Clinical Research Organizations
  • 11.7. Market Attractiveness Analysis

12. Competition Landscape

  • 12.1. Market Share Analysis, 2025
  • 12.2. Market Structure
    • 12.2.1. Competition Intensity Mapping By Market
    • 12.2.2. Competition Dashboard
  • 12.3. Company Profiles (Details - Overview, Financials, Strategy, Recent Developments)
    • 12.3.1. Roche Holding
      • 12.3.1.1. Overview
      • 12.3.1.2. Segments and Products
      • 12.3.1.3. Key Financials
      • 12.3.1.4. Market Developments
      • 12.3.1.5. Market Strategy
    • 12.3.2. Illumina
    • 12.3.3. IDL Biotech
    • 12.3.4. Agilent Technologies
    • 12.3.5. Olympus Corporation
    • 12.3.6. Philips Healthcare
    • 12.3.7. Abbott Molecular
    • 12.3.8. Bio-Rad Laboratories, Inc.
    • 12.3.9. Thermo Fisher Scientific, Inc. (Qiagen N.V.)
    • 12.3.10. Danaher Corporation (Cepheid)
    • 12.3.11. GE Healthcare
    • 12.3.12. Pacific Edge
    • 12.3.13. Nonacus Limited
    • 12.3.14. KDx Diagnostics Inc.
    • 12.3.15. Sysmex Europe SE

13. Appendix

  • 13.1. Research Methodology
  • 13.2. Research Assumptions
  • 13.3. Acronyms and Abbreviations